Bone marrow stem cell therapy for recessive dystrophic epidermolysis bullosa

Maija Ht Kiuru, Munenari Itoh, Mitchell S. Cairo, Angela M. Christiano

Research output: Contribution to journalReview article

27 Citations (Scopus)

Abstract

Recessive dystrophic epidermolysis bullosa (RDEB) is a severe inherited blistering disease caused by mutations in the type VII collagen gene, resulting in defective anchoring fibrils at the epidermal-dermal junction. At present, no curative treatment for RDEB exists. Mounting evidence on reprogramming of bone marrow stem cells into skin has prompted the authors and others to develop novel strategies for treatment of RDEB. The rationale for bone marrow stem cell therapies for RDEB is based on the evidence that bone marrow-derived cells are guided into becoming skin cells, given the right microenvironment. Preclinical studies in mouse models have shown that wild-type bone marrow-derived cells can ameliorate the phenotype of RDEB and improve survival by restoring the expression of type VII collagen and the anchoring fibrils. At present, several clinical studies are ongoing around the world to study the therapeutic effects of bone marrow stem cell transplantation for RDEB. These studies provide a framework for future development of standardized, effective methods for stem cell transplantation to cure severe inherited skin diseases, including RDEB.

Original languageEnglish (US)
Pages (from-to)371-382
Number of pages12
JournalDermatologic Clinics
Volume28
Issue number2
DOIs
StatePublished - Apr 2010
Externally publishedYes

Fingerprint

Epidermolysis Bullosa Dystrophica
Cell- and Tissue-Based Therapy
Bone Marrow Cells
Stem Cells
Collagen Type VII
Stem Cell Transplantation
Skin
Therapeutic Uses
Bone Marrow Transplantation
Skin Diseases
Phenotype
Mutation
Therapeutics

Keywords

  • Bone marrow stem cells
  • Bone marrow transplantation
  • Clinical trial
  • Recessive dystrophic epidermolysis bullosa
  • Stem cell microenvironment

ASJC Scopus subject areas

  • Dermatology

Cite this

Bone marrow stem cell therapy for recessive dystrophic epidermolysis bullosa. / Kiuru, Maija Ht; Itoh, Munenari; Cairo, Mitchell S.; Christiano, Angela M.

In: Dermatologic Clinics, Vol. 28, No. 2, 04.2010, p. 371-382.

Research output: Contribution to journalReview article

Kiuru, Maija Ht ; Itoh, Munenari ; Cairo, Mitchell S. ; Christiano, Angela M. / Bone marrow stem cell therapy for recessive dystrophic epidermolysis bullosa. In: Dermatologic Clinics. 2010 ; Vol. 28, No. 2. pp. 371-382.
@article{75551b55047b429ebe7a24ad22481b5a,
title = "Bone marrow stem cell therapy for recessive dystrophic epidermolysis bullosa",
abstract = "Recessive dystrophic epidermolysis bullosa (RDEB) is a severe inherited blistering disease caused by mutations in the type VII collagen gene, resulting in defective anchoring fibrils at the epidermal-dermal junction. At present, no curative treatment for RDEB exists. Mounting evidence on reprogramming of bone marrow stem cells into skin has prompted the authors and others to develop novel strategies for treatment of RDEB. The rationale for bone marrow stem cell therapies for RDEB is based on the evidence that bone marrow-derived cells are guided into becoming skin cells, given the right microenvironment. Preclinical studies in mouse models have shown that wild-type bone marrow-derived cells can ameliorate the phenotype of RDEB and improve survival by restoring the expression of type VII collagen and the anchoring fibrils. At present, several clinical studies are ongoing around the world to study the therapeutic effects of bone marrow stem cell transplantation for RDEB. These studies provide a framework for future development of standardized, effective methods for stem cell transplantation to cure severe inherited skin diseases, including RDEB.",
keywords = "Bone marrow stem cells, Bone marrow transplantation, Clinical trial, Recessive dystrophic epidermolysis bullosa, Stem cell microenvironment",
author = "Kiuru, {Maija Ht} and Munenari Itoh and Cairo, {Mitchell S.} and Christiano, {Angela M.}",
year = "2010",
month = "4",
doi = "10.1016/j.det.2010.02.004",
language = "English (US)",
volume = "28",
pages = "371--382",
journal = "Dermatologic Clinics",
issn = "0733-8635",
publisher = "W.B. Saunders Ltd",
number = "2",

}

TY - JOUR

T1 - Bone marrow stem cell therapy for recessive dystrophic epidermolysis bullosa

AU - Kiuru, Maija Ht

AU - Itoh, Munenari

AU - Cairo, Mitchell S.

AU - Christiano, Angela M.

PY - 2010/4

Y1 - 2010/4

N2 - Recessive dystrophic epidermolysis bullosa (RDEB) is a severe inherited blistering disease caused by mutations in the type VII collagen gene, resulting in defective anchoring fibrils at the epidermal-dermal junction. At present, no curative treatment for RDEB exists. Mounting evidence on reprogramming of bone marrow stem cells into skin has prompted the authors and others to develop novel strategies for treatment of RDEB. The rationale for bone marrow stem cell therapies for RDEB is based on the evidence that bone marrow-derived cells are guided into becoming skin cells, given the right microenvironment. Preclinical studies in mouse models have shown that wild-type bone marrow-derived cells can ameliorate the phenotype of RDEB and improve survival by restoring the expression of type VII collagen and the anchoring fibrils. At present, several clinical studies are ongoing around the world to study the therapeutic effects of bone marrow stem cell transplantation for RDEB. These studies provide a framework for future development of standardized, effective methods for stem cell transplantation to cure severe inherited skin diseases, including RDEB.

AB - Recessive dystrophic epidermolysis bullosa (RDEB) is a severe inherited blistering disease caused by mutations in the type VII collagen gene, resulting in defective anchoring fibrils at the epidermal-dermal junction. At present, no curative treatment for RDEB exists. Mounting evidence on reprogramming of bone marrow stem cells into skin has prompted the authors and others to develop novel strategies for treatment of RDEB. The rationale for bone marrow stem cell therapies for RDEB is based on the evidence that bone marrow-derived cells are guided into becoming skin cells, given the right microenvironment. Preclinical studies in mouse models have shown that wild-type bone marrow-derived cells can ameliorate the phenotype of RDEB and improve survival by restoring the expression of type VII collagen and the anchoring fibrils. At present, several clinical studies are ongoing around the world to study the therapeutic effects of bone marrow stem cell transplantation for RDEB. These studies provide a framework for future development of standardized, effective methods for stem cell transplantation to cure severe inherited skin diseases, including RDEB.

KW - Bone marrow stem cells

KW - Bone marrow transplantation

KW - Clinical trial

KW - Recessive dystrophic epidermolysis bullosa

KW - Stem cell microenvironment

UR - http://www.scopus.com/inward/record.url?scp=77952483707&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952483707&partnerID=8YFLogxK

U2 - 10.1016/j.det.2010.02.004

DO - 10.1016/j.det.2010.02.004

M3 - Review article

C2 - 20447506

AN - SCOPUS:77952483707

VL - 28

SP - 371

EP - 382

JO - Dermatologic Clinics

JF - Dermatologic Clinics

SN - 0733-8635

IS - 2

ER -